Collaborating on Individualized Management Solutions for Pediatric Patients with Moderate-to-Severe Atopic Dermatitis

ActionED

More than one-third of pediatric patients with atopic dermatitis (AD) have moderate to severe disease, with large areas of dry skin, frequent itching, and skin redness, that strongly impedes daily routines and negatively affects their sleep, mental health, and overall quality of life along with significant impacts on families. Unfortunately, suboptimal assessment of AD in routine clinical practice can lead to delayed diagnosis, underappreciation of disease severity, and delays in treatment initiation, referral to specialists, and treatment intensification.

Although basic skin care and topical therapies can be very effective in treating mild cases of AD, patients with moderate to severe disease generally require systemic therapy to achieve long-term disease control. The discovery of the role of type 2 inflammatory pathways in AD has led to new concepts in AD pathogenesis, and subsequently, to novel treatment strategies. Yet evidence indicates that there is discordance between patients’/caregivers’ and clinicians’ perception of severity and disease burden, which may contribute to suboptimal treatment.

To improve evaluation, coordination of care, and treatment practices in pediatric patients with AD, clinicians in both primary care and specialty settings must continually assess and adapt to evolving diagnostic and therapeutic strategies to ensure proactive, patient-centric treatment to improve outcomes. To support translation and implementation of the latest evidence into routine clinical practice, this program provides participants with a personalized learning experience. Complete an initial assessment, receive individualized recommendations for education, and access tools and resources to develop an action plan for improving the care of pediatric patients with atopic dermatitis.

Faculty: Elaine Siegfried, MD; Adelaide Hebert, MD; Bob Geng, MD

Release Date: March 31, 2026

Expiration Date: March 31, 2027